Incorporating pharmacoequity in the formulary review and evaluation process: Opportunities for health-system P&T committees to address health disparities and inequities

Donald C Moore; Angela Colella; Janine S Douglas; Elizabeth A Shlom; Joshua P Vanderloo; Folashade Alabi

doi:10.1093/ajhp/zxae370

Incorporating pharmacoequity in the formulary review and evaluation process: Opportunities for health-system P&T committees to address health disparities and inequities

Am J Health Syst Pharm. 2024 Dec 5:zxae370. doi: 10.1093/ajhp/zxae370. Online ahead of print.

Authors

Donald C Moore¹, Angela Colella², Janine S Douglas³, Elizabeth A Shlom⁴, Joshua P Vanderloo⁵, Folashade Alabi⁶

Affiliations

¹ Division of Pharmacy, Atrium Health Levine Cancer, Charlotte, NC, USA.
² Advocate Health, Milwaukee, WI, USA.
³ Intermountain Health, Salt Lake City, UT, USA.
⁴ Institution, Lambertville, NJ, USA.
⁵ UW Health, Madison, WI, USA.
⁶ Medical Education, The Lockwood Group, Stamford, CT, USA.

PMID: 39656923
DOI: 10.1093/ajhp/zxae370

Abstract

In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

© American Society of Health-System Pharmacists 2024. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].